Home > Insider Trading > Filing (0001127602-11-007663)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
875045	Biogen Idec Inc.	BIIB	Biological Products, (No Disgnostic Substances) (2836)	330112644

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1226289	Eric Craig Schneier	Biogen Idec Inc. 133 Boston Post Road Weston MA 02493	Evp, Hr, Public Affairs & Comm	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2011-02-23	4,077	$0.00	20,513	No	4	M	Direct
Common Stock	Acquisiton	2011-02-23	953	$0.00	21,466	No	4	M	Direct
Common Stock	Disposition	2011-02-23	1,295	$66.76	20,171	No	4	F	Direct
Common Stock	Disposition	2011-02-23	303	$66.76	19,868	No	4	F	Direct
Common Stock	Acquisiton	2011-02-25	9,725	$49.31	29,593	No	4	M	Direct
Common Stock	Disposition	2011-02-25	9,725	$68.20	19,868	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	F	Direct
No	4	F	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Unit	Disposition	2011-02-23	4,077	$0.00	4,077	$0.00
Common Stock	Restricted Stock Unit	Disposition	2011-02-23	953	$0.00	953	$0.00
Common Stock	Restricted Stock Unit	Disposition	2011-02-23	1,086	$0.00	0	$0.00
Common Stock	Stock Option (Right to Buy)	Disposition	2011-02-25	9,725	$0.00	9,725	$49.31

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
20,381	2014-02-23	No	4	M	Direct
19,428	2014-02-23	No	4	M	Direct
18,342	2014-02-23	No	4	J	Direct
0	2017-02-11	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	460	Indirect	By Spouse

Footnotes

Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
There is no conversion or exercise price for this stock unit.
The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).
This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.
Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC rule 16(b)-3(d).
The stock option becomes exercisable in four (4) equal annual installments, commencing one year after the grant date of 02/12/07.